Protect Beneficiaries from Middlemen Act

H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2548/S. 1241, Sanctioning Russia Act of 2025 H.R. 2665/S. 1272, Trade Review Act of 2025 H.R. 3193, United States-Republic of Korea Digital Trade Enforcement Act H.R. 5197/S. 3103, A bill to authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries H.R. 5926, Mexican Energy Trade Enforcement Act H.R. 6194/S. 2934, Protecting Americans from Russian Litigation Act of 2025 H.R. 6500, AGOA Extension Act H.R. 6504, Haiti Economic Lift Program Extension Act S. 3399, Digital Trade Promotion Act S. 3841, Last Sale Valuation Act of 2026 H.J. Res. 72, Relating to the National Emergency by the President on February 1, 2025 S.J. Res. 77, A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada S.J. Res. 88, A joint resolution terminating the national emergency declared to impose global tariffs Various issues relating to U.S.-Korea digital trade and services; Congressional tariff authority; Adoption and Procedures of the Section 232 Steel and Aluminum Tariff Inclusions Process; reform of the World Trade Organization (WTO); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Inflation Reduction Act, (P.L. 117-169); pharmaceutical price controls; patent-related issues, including patent linkage, patent term restoration, patent examination practices, and patent quality measures; regulatory data protection; efforts related to the U.S. International Development Finance Corporation (DFC); efforts related to ensuring a streamlined tariff refund process; efforts related to the advancement of tax treaties with Poland and Croatia; efforts related to identifying unfair foreign trade practices; efforts related to the extension of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); efforts related to regulations issued by the Bank of Central African States (BEAC); efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to opposing international imposition of digital services taxes; efforts related to supporting strong digital trade rules; efforts to modify permanent normal trade relations treatment with China; U.S. economic and commercial relations with key trading partners across the globe; efforts to implement an outbound investment screening mechanism; efforts related to modernizing customs processes and updating tariff application procedures, including revisions to the de minimis statute; efforts related to the development of trade relations in the Indo-Pacific; efforts related to the development of trade relations in the Americas region; efforts related to the joint review of the U.S.-Mexico-Canada Agreement (USMCA); implementation and enforcement of U.S. free-trade agreements in force with 20 countries; implementation and enforcement of the agreements and ongoing negotiations of the WTO; trade policy concerns regarding customs duties on electronic transmissions; implementation of U.S. sanctions on Russia, including those related to Russias invasion of Ukraine; efforts related to sustaining momentum on providing aid to Ukraine; efforts related to reauthorization of the Export-Import Bank (Ex-Im Bank); reforms or changes to export controls; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; IP issues relating to internet counterfeiting and digital piracy; IP issues relating to artificial intelligence; Global Internet Governance; policies and regulations restricting outbound data flows and data transfers; digital-related policies in the G20, G7, OECD, WTO, United Nations, and other international fora; digital trade policy considerations including cross-border data flows, digital service taxes, and issues of forced data localization, and forced disclosure of source code; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international digital health policies; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; consumer protection policy and related regulations; steel and aluminum tariffs; digital and tech sovereignty and sovereign cloud; IP issues at the WTO and the World Intellectual Property Organization; the EUs General Pharmaceutical Legislation; IP issues in Latin America, including enforcement of trade agreements and compulsory licenses and general IP standards and practices in Argentina, Mexico, Brazil, Colombia, and Chile; IP issues in India; USTRs Special 301 report and Review of Notorious Markets for Counterfeiting and Piracy; intersection of tariff-related policy and IP implications; U.S. Patent and Trademark Office IP Attache program; imposition of potential patent valuation fees; foreign pricing of pharmaceutical products; Most Favored Nation (MFN) reference pricing; ongoing practice of discretionary denials at the Patent Trial and Appeal Board; international competition policy, specifically FTC and DOJ involvement in the European Unions implementation of the EU Digital Markets Act; International Emergency Economic Powers Act (50 U.S.C. 1701(a)(b)) (IEEPA); IEEPA tariff refund implementation following the Supreme Courts decision in Learning Resources v. Trump; Directive (EU) 2024/2853 of the European Parliament and of the Council of 23 October 2024 on liability for defective products and repealing Council Directive 85/374/EEC; Mexicos Tax Administration Service (SAT); recommended changes to the EUs Corporate Sustainability Due Diligence Directive (CS3D); supply chain and defense industrial base issues; development of the National Defense Authorization Act for Fiscal Year 2027

Client expense: $19,750,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)

H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic drugs applications and approvals H.R. 946 - ORPHAN Cures Act - Rep. Joyce, John - Medicare Drug Negotiation Program H.R. 950 - Saving Seniors Money on Prescriptions Act - Rep. Landsman, Greg - PBM reporting requirements for MA/Part D plans. H.R. 1117 - Responsibility in Drug Advertising Act - Rep. DeLauro, Rosa - Direct-to-consumer ads H.R. 1244 - Reducing Drug Prices for Seniors Act - Rep. Davis, Donald - Coinsurance for Part D drugs H.R. 2214 - DRUG Act - Rep. Miller-Meeks, Mariannette - PBM contracts H.R. 2450 - Prescription Drug Transparency and Affordability Act - Rep. McDonald Rivet, Kristen - PBM transparency H.R. 3493 - Global Fairness in Drug Pricing Act - Rep. Khanna, Ro - Prescription drug international reference pricing H.R. 3546 - Prescription Drug Price Relief Act - Rep. Khanna, Ro - Prescription drug patent reform H.R. 3775 - Fair Prescription Drug Prices for Americans Act - Rep. Van Drew, Jefferson - Prescription drug and biological product international reference pricing H.R. 3789 - DTC Act - Rep. Taylor, David - Direct-to-consumer prescription advertising transparency H.R. 4139 - Cutting Copays Act - Rep. McGarvey, Morgan - Medicare cost-sharing for generic drugs H.R. 4231 - Treat and Reduce Obesity Act - Rep. Kelly, Mike - Medicare coverage of obesity drugs H.R. 4317 - PBM Reform Act - Rep. Carter, Earl L. Buddy - PBM contracting requirements and transparency H.R. 4605 - End Prescription Drug Ads Now Act - Rep. Nadler, Jerrold - Ban on DTC drug ads H.R. 4623 - Plain Prescription Prices Act - Rep. Williams, Nikema - Transparency requirements for DTC drug ads H.R. 5094 - Protect Patients from Costly Care Act - Rep. Pappas, Chris - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program H.R. 5197 - Protect Beneficiaries from Middlemen Act - Rep. Malliotakis, Nicole - Medicare cost-sharing limit for drugs H.R. 6255 - Affordable Insulin Now Act - Rep. Craig, Angie - require cost-sharing for certain insulin products S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manage Transparency - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock, Raphael - Drug copay caps S. 652 - Protecting Patients from Deceptive Drugs Ads Act - Sen. Durbin, Richard - Drug advertising requirements S. 882 - Patients Before Middlemen Act - Sen. Blackburn, Marsha - PBM reforms S. 891 - Bipartisan Health Care Act - Sen. Wyden, Ron - PBM reforms and transparency S. 1040 - Drug Competition Enhanced Act - Sen. Cornyn, John - Drug patent reform S. 1041 - Affordable Prescriptions for Patients Act - Sen. Cornyn, John - Patent issues S. 1095 - Stop STALLING Act - Sen. Klobuchar, Amy - Drug patent reform S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - Drug patent reform S. 1414 - Expedited Access to Biosimilars Act - Sen. Paul, Rand - Biosimilars assessment and approval S. 1587 - Fair Prescription Drug Prices for Americans Act - Sen. Hawley, Josh - Prescription drug international reference pricing S. 1753 - End Price Gouging for Medications Act - Sen. Merkley, Jeff - Prescription drug international reference pricing S. 1818 - Prescription Drug Price Relief Act - Sen. Sanders, Bernard - Prescription drug patent reform S. 1954 - Biosimilar Red Tape Elimination Act - Sen. Lee, Mike - Biological product assessment and approval S. 1973 - Treat and Reduce Obesity Act - Sen. Cassidy, Bill - Medicare coverage for obesity drugs S. 2345 - Short on Competition Act - Sen. Klobuchar, Amy - Expedited approval for generic drugs S. 2447 - Repealing the Trump Sick Tax Act - Sen. Welch, Peter - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program S. 2620 - REMEDY Act - Sen. Durbin, Richard - Expedited approvals for certain drug approvals Issues related to the implementation of Inflation Reduction Act - Medicare negotiation; cost-sharing and coverage of weight loss drugs/GLP-1s; high priced drugs; patent reforms; Pharmacy Benefit Managers; PBM related issues; and copay coupons.

H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1625, the HELP Extension Act H.R. 1743/S. 776, Undertaking Negotiations on Investment and Trade for Economic Dynamism (UNITED) Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2548/S. 1241, Sanctioning Russia Act of 2025 H.R. 2665/S. 1272, Trade Review Act of 2025 H.R. 3193, United States-Republic of Korea Digital Trade Enforcement Act H.R. 5197/S. 3103, A bill to authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries H.R. 5926, Mexican Energy Trade Enforcement Act H.R. 6194/S. 2934, Protecting Americans from Russian Litigation Act of 2025 H.R. 6500, AGOA Extension Act H.R. 6504, Haiti Economic Lift Program Extension Act S. 2296, National Defense Authorization Act for Fiscal Year 2026 S. 3399, Digital Trade Promotion Act S.J.Res. 77, A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada S.J.Res. 88, A joint resolution terminating the national emergency declared to impose global tariffs S.J.Res. 37, A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada S.J.Res. 49, A joint resolution terminating the national emergency declared to impose global tariffs Draft legislation titled Haitian Hemispheric Opportunity through Partnership Encouragement Act Draft legislation titled AGOA Renewal and Improvement Act Draft legislation titled the Americas Act Proposed Rule, Federal Trade Commission; Business Opportunity Rule (16 CFR 437, January 13, 2025) Advanced Notice of Proposed Rulemaking, Federal Trade Commission; Earnings Claims Rule Regarding Multi-Level Marketing (Additional Provisions) (16 CFR Part 462, January 13, 2025) Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients (90 Fed. Reg. 15,951-15,952, April 16, 2025) Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices (90 Fed. Reg. 46,383, September 26, 2025) Various issues relating to U.S.-Korea digital trade and services; Generalized System of Preferences (GSP) reauthorization; Adoption and Procedures of the Section 232 Steel and Aluminum Tariff Inclusions Process; fifty-percent (50%) tariff on imports from Brazil; ratification of the Assignment of Receivables in International Trade Convention; reform of the World Trade Organization (WTO); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Uyghur Forced Labor Prevention Act (UFLPA) (P.L. 117-78); implementation of the African Growth and Opportunity Act (P.L. 106-200); implementation of the Inflation Reduction Act, (P.L. 117-169); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); pharmaceutical price controls; implementation of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent-related issues, including patent linkage, patent term restoration, patent examination practices, and patent quality measures; regulatory data protection; efforts related to identifying unfair foreign trade practices; efforts related to the reauthorization of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); efforts related to the reauthorization of the U.S. International Development Finance Corporation (DFC); efforts related to the advancement of tax treaties with Poland and Croatia; efforts related to regulations issued by the Bank of Central African States (BEAC); efforts related to the National Defense Authorization Act for Fiscal Year 2026; efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to opposing international imposition of digital services taxes; related efforts supporting strong digital trade rules; efforts to modify permanent normal trade relations treatment with China; U.S. economic and commercial relations with key trading partners across the globe; efforts to draft and implement an outbound investment screening mechanism; efforts related to establishing a domestic carbon border tax mechanism, foreign pollution fees; efforts related to modernizing customs processes and updating tariff application procedures, including revisions to the de minimis statute; efforts related to the development of trade relations in the Indo-Pacific; efforts related to the development and negotiation of the U.S.-Taiwan Initiative on 21st Century Trade; efforts related to the development of trade relations in the Americas region; efforts related to the development and negotiation of the U.S.-UK Dialogue on the Future of Atlantic Trade; efforts related to the development and negotiation of the U.S.-Kenya Strategic Trade and Investment Partnership; efforts related to the joint review of the U.S.-Mexico-Canada Agreement (USMCA); implementation and enforcement of U.S. free-trade agreements in force with Canada and Mexico (the United States-Mexico-Canada Agreement), the Dominican Republic-Central America Free Trade Agreement (CAFTA-DR FTA), Colombia and South Korea; implementation and enforcement of the agreements and ongoing negotiations of the World Trade Organization (WTO); efforts to significantly revise U.S. antidumping and countervailing duty law; Trade Promotion Authority (TPA) reauthorization and reform; U.S.-EU energy and sustainability cooperation; EU and international tax policy including digital tax proposals; U.S.-EU negotiations on a legal data transfer mechanism; U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; European Cybersecurity Certification Scheme for Cloud Services (EUCS); EU Carbon Border Adjustment Mechanism; China's intellectual property regime, industrial policies, and cyber security; implementation of the U.S.-China economic and trade agreement; United States-India Trade Policy Forum and associated bilateral trade negotiations; efforts related to sustaining momentum on providing aid to Ukraine; efforts to provide financial support, trade facilitation, and infrastructure support to the African Continental Free Trade Area (AfCFTA); IP issues relating to internet counterfeiting and digital piracy; IP issues relating to artificial intelligence; implementation of U.S. sanctions on Russia, including those related to Russias threats to and invasion of Ukraine; reforms to export controls; Global Internet Governance; network fees; Global Cross Border Privacy Rules Forum; policies and regulations restricting outbound data flows and data transfers; digital-related policies in the G20, G7, OECD, WTO, United Nations, and other international fora; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; efforts to modernize the Committee on Foreign Investment in the United States (CFIUS); efforts related to the Export-Import Bank (Ex-Im Bank); digital trade policy considerations including cross-border data flows, digital service taxes, and issues of forced data localization, and forced disclosure of source code; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international digital health policies; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; consumer protection policy and related regulations; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; digital and tech sovereignty and sovereign cloud; tariff authority letter supporting Congress reclaiming its constitutional tariff authority; U.S.-Brazil trade; U.S.-Columbia Trade Promotion Agreement; Pacific Digital Trade Agreements; U.S.-Chile Tax Treaty, Convention for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital; U.S. Trade Representative section 301 investigation of Frances digital services tax; efforts to pass the Miscellaneous Tariff bill; Russian sovereign debt; Commercial Service Office in Bangladesh; Indo-Pacific Economic Framework and associated issues, digital trade de minimis level for duty free clearance of low value goods, competition provisions; recommendations for Export Controls Cooperation at the U.S.-EU Trade and Technology Council; adoption of digital clothing labels; IP issues at the World Trade Organization and the World Intellectual Property Organization; the EUs General Pharmaceutical Legislation; IP issues in Latin America, including enforcement of trade agreements and compulsory licenses and general IP standards and practices in Brazil and Chile; IP issues in India; USTRs Special 301 report and Review of Notorious Markets for Counterfeiting and Piracy; intersection of tariff-related policy and IP implications; U.S. Patent and Trademark Office IP Attache program; issues related to the imposition of potential patent valuation fees; issues related to the ongoing practice of discretionary denials at the Patent Trial and Appeal Board; international competition policy, specifically FTC and DOJ involvement in the European Unions implementation of the EU Digital Markets Act; proposal for General License Authorizing Private Commercial Arbitration Proceedings Involving Blocked Persons; The United States Trade Representatives decision to withdraw support for digital trade in the context of World Trade Organizations e-commerce negotiations; support for robust global framework for facilitation of digital trade through the ongoing joint statement initiative on e-commerce (JSI); Indonesia Ministry of Trade Import Licensing Regulations; International Emergency Economic Powers Act (50 U.S.C. 1701(a)(b)) (IEEPA); conduction of South Africas competition reviews; 2019 Agreement Suspending the Antidumping Investigation on Fresh Tomatoes from Mexico; continuation of the Moratorium on Customs Duties on Electronic Transmissions; recommended changes to the EUs Corporate Sustainability Due Diligence Directive (CS3D); Executive Order 14193, Imposing Duties to Address the Flow of Illicit Drugs Across Our Northern Border; supply chain and defense industrial base issues; Foreign Assistance Act for Fiscal Year 2026

H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic drugs applications and approvals H.R. 946 - ORPHAN Cures Act - Rep. Joyce, John - Medicare Drug Negotiation Program H.R. 950 - Saving Seniors Money on Prescriptions Act - Rep. Landsman, Greg - PBM reporting requirements for MA/Part D plans H.R. 1117 - Responsibility in Drug Advertising Act - Rep. DeLauro, Rosa - Direct-to-consumer ads H.R. 1244 - Reducing Drug Prices for Seniors Act - Rep. Davis, Donald - Coinsurance for Part D drugs H.R. 2214 - DRUG Act - Rep. Miller-Meeks, Mariannette - PBM contracts H.R. 2450 - Prescription Drug Transparency and Affordability Act - Rep. McDonald Rivet, Kristen - PBM transparency H.R. 3493 - Global Fairness in Drug Pricing Act - Rep. Khanna, Ro - Prescription drug international reference pricing H.R. 3546 - Prescription Drug Price Relief Act - Rep. Khanna, Ro - Prescription drug patent reform H.R. 3775 - Fair Prescription Drug Prices for Americans Act - Rep. Van Drew, Jefferson - Prescription drug and biological product international reference pricing H.R. 3789 - DTC Act - Rep. Taylor, David - Direct-to-consumer prescription advertising transparency H.R. 4139 - Cutting Copays Act - Rep. McGarvey, Morgan - Medicare cost-sharing for generic drugs H.R. 4231 - Treat and Reduce Obesity Act - Rep. Kelly, Mike - Medicare coverage of obesity drugs H.R. 4317 - PBM Reform Act - Rep. Carter, Earl L. Buddy - PBM contracting requirements and transparency H.R. 4605 - End Prescription Drug Ads Now Act - Rep. Nadler, Jerrold - Ban on DTC drug ads H.R. 4623 - Plain Prescription Prices Act - Rep. Williams, Nikema - Transparency requirements for DTC drug ads H.R. 5094 - Protect Patients from Costly Care Act - Rep. Pappas, Chris - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program H.R. 5197 - Protect Beneficiaries from Middlemen Act - Rep. Malliotakis, Nicole - Medicare cost-sharing limit for drugs S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manage Transparency - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock, Raphael - Drug copay caps S. 652 - Protecting Patients from Deceptive Drugs Ads Act - Sen. Durbin, Richard - Drug advertising requirements S. 882 - Patients Before Middlemen Act - Sen. Blackburn, Marsha - PBM reforms S. 891 - Bipartisan Health Care Act - Sen. Wyden, Ron - PBM reforms and transparency S. 1040 - Drug Competition Enhanced Act - Sen. Cornyn, John - Drug patent reform S. 1041 - Affordable Prescriptions for Patients Act - Sen. Cornyn, John - Patent issues S. 1095 - Stop STALLING Act - Sen. Klobuchar, Amy - Drug patent reform S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - Drug patent reform S. 1414 - Expedited Access to Biosimilars Act - Sen. Paul, Rand - Biosimilars assessment and approval S. 1587 - Fair Prescription Drug Prices for Americans Act - Sen. Hawley, Josh - Prescription drug international reference pricing S. 1753 - End Price Gouging for Medications Act - Sen. Merkley, Jeff - Prescription drug international reference pricing S. 1818 - Prescription Drug Price Relief Act - Sen. Sanders, Bernard - Prescription drug patent reform S. 1954 - Biosimilar Red Tape Elimination Act - Sen. Lee, Mike - Biological product assessment and approval S. 1973 - Treat and Reduce Obesity Act - Sen. Cassidy, Bill - Medicare coverage for obesity drugs S. 2345 - Short on Competition Act - Sen. Klobuchar, Amy - Expedited approval for generic drugs S. 2447 - Repealing the Trump Sick Tax Act - Sen. Welch, Peter - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program S. 2620 - REMEDY Act - Sen. Durbin, Richard - Expedited approvals for certain drug approvals Issues related to the implementation of Inflation Reduction Act - Medicare negotiation; coverage of weight loss drugs; high priced drugs; patent reforms; Pharmacy Benefit Managers; PBM related issues; and copay coupons.